preview rx strateg review
expect report earn earli august think
expect moder go quarter given time
revenu neg suppli chain impact rx invest higher
revis model better align rx dynam
though full-year estim unchang expect sale
vs prior adjust ep vs prior
primari potenti posit event remain unveil
valu creation roadmap ahead event think
share present compel valu ntm consensu ebitda vs
five-year ten-year averag respect
expect weak rx gener robust growth
suppli chain disrupt scopolamin neg impact
expect neg affect product return
market addit launch major unnam
product lead repres approxim
year total rx revenu rx revenu guidanc
implic revenu may declin approxim
increas
expect modest growth over-the-counter busi
continu expect modest growth chca
chci driven new product launch
market share gain partial off-set weak price competit
call investor want know strateg review
howev expect reveal much regard valu
creation roadmap perrigo manag busi
formul long-term strategi expect substant updat
late fall refer roadshow updat addit perspect
model updat revis quarterli estim view
variou factor includ suppli chain disrupt time product
launch fx invest lead year total adjust ep
year total estim
valu use discount cash flow model base fcff
discount rate termin ev/ebitda multipl
chang made note
price target usd chang
buy chang
page analyst certif
import disclosur
perform rel
co plc engag product
over-the-count consum good
profit loss summari
growth margin
domin share privat label store brand
market solid presenc european brand over-the-counter
chca busi benefit renew regulatori
legisl focu over-the-counter
account oversight improv
chci busi stabil look pois growth
rx busi proven resili
challeng extern oper margin stabil high
low rang
recent hire new ceo uwe rhrhoff track
record effici oper typic deliv
promis think knowledg eu market help
continu success turnaround chci busi
valu use discount cash flow model base
fcff discount rate termin ev/ebitda
multipl
chang net debt
average cost debt
risk invest thesi
monograph reform bill pass could neg
impact assumpt increas innov penetr
over-the-counter medicin true fda act find
way eas rx-to-otc pathway risk thesi
includ increas competit gener pressur rx
busi expect turnaround eu stall
regulatori risk price risk litig risk busi
exhibit revis model better align rx gener dynam
exhibit select financi estim bcm vs consensu vs guidanc
million unless otherwis note
note full-year adjust ep rang prior proair though yet
offici updat full-year guidanc exhibit remov high end low end
rang previous provid
estim trade averag
pharma peer prgo valuat compel
rel select specialti pharmaceut
pchp compani prgo valuat also compel
exhibit nearli pariti rel forward ev/ebitda basi
vs trade far averag premium
rel select person household product
rel
valuat risk
price target base discount cash flow termin multipl method
discount rate termin ev/ebitda multipl reduct price
target due entir push back potenti launch gener proair
main risk thesi relat view regul legisl
regulatori legisl solut implement reduc
prescript drug cost inflat includ increas access non-prescript drug
posit impact think assumpt model
call acceler fundament may optimist risk thesi
includ increas competit gener pressur perrigo rx busi
expect turnaround eu stall regulatori risk price risk litig
risk busi develop risk among other
profit loss account
million
sale
sale
sale
sale
sale
sale
sale
total expens
total expens
total expens
total expens
sale
sale
 year
reconcili gaap
reconcili gaap
reconcili gaap
reconcili gaap
million
cash equival
prepaid expens
properti plant equip net
goodwil
payrol relat tax
accumul incom loss
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
million
depreci amort
loss acquisition-rel fx
chang financi asset
tysabri chang fair valu
incom tax benefit stock option
excess tax benefit stock transact
loss sale invest
loss sale busi
loss extinguish debt
loss equiti method invest
amort debt discount premium
chang work capit
chang work capit
chang work capit
chang work capit
payrol relat tax
total chang work capit
oper activ
oper activ
oper activ
oper activ
acquisit busi
proce royalti right
settlement acquisition-rel fx
acquisit intang asset
addit properti equip
proce sale secur
proce sale pp
proce sale tysabri
proce sale busi
invest activ
invest activ
invest activ
invest activ
purchas non-controlling interest
repay long-term debt
borrow repay revolv
proce debt issuanc
premium earli retir debt
share withheld tax liabil
excess tax benefit stock transact
issuanc common stock
equiti issuanc
repurchas common stock
settlement conting consider
financ activ
financ activ
financ activ
financ activ
effect exchang rate cash
net chang cash
begin cash equival
end cash equival
end cash equival
end cash equival
end cash equival
capital-expenditure sale
